MAY 19, 2009

Biotech M&A - How to Sell Your Company in an Environment of Consolidation

Source: BIO International Convention, Atlanta, GA

Consolidation among biotech companies is an increasingly important and expanding trend in the life-science arena. As large biotechs face the upcoming expiration of patents on many of their important drugs, they are focusing on mergers and acquisitions as a means of expanding their product pipeline. Smaller biotechs offering both proven drugs as well as promising products in development are prime targets for acquisition. Moreover, the challenging economic environment has made it difficult or impossible for many smaller biotech companies to fund research and development making a sale more necessary or desirable. Scisive Consulting examines how emerging biotechs can prepare for the possibility of being acquired, the types of M&A biotech transactions, and the ways in which target companies can successfully navigate through the acquisition process. Please request a free copy of the Scisive presentation #0905 at This e-mail address is being protected from spambots. You need JavaScript enabled to view it
– Robert J. Easton, Chairman, Scisive Consulting LP